Dangerous Drug: Idarubicin Hydrochloride(eye da roo’ bi sin)
Idamycin PFS
PREGNANCY CATEGORY D
Drug Classes
Antibiotic (anthracycline)
Antineoplastic
Therapeutic Actions
Cytotoxic: Binds to DNA and inhibits DNA synthesis in susceptible cells.
Indications
In combination with other approved antileukemic drugs for the treatment of AML in adults
Orphan drug uses: Acute nonlymphocytic leukemia and ALL in pediatric patients
Unlabeled uses: Breast cancer, autologous hematopoietic stem-cell transplantation, chronic myelogenous leukemia
Contraindications and Cautions
Contraindicated with allergy to idarubicin, other anthracycline antibiotics; myelosuppression; cardiac disease; pregnancy; lactation.
Use cautiously with impaired hepatic or renal function.
Available Forms
Injection—1 mg/mL
Dosages
Adults
Induction therapy in adults with AML: 12 mg/m2 daily for 3 days by slow IV injection (10–15 min) in combination with cytarabine. Cytarabine may be administered as 100 mg/m2 daily given by continuous infusion for 7 days or as a 25-mg/m2 IV bolus followed by 200 mg/m2 daily for 5 days by continuous infusion. A second course may be administered when toxicity has subsided, if needed, at a 25% dose reduction.
Consolidation therapy in adults with AML: 10–12 mg/m2/day by slow IV infusion for 2 days.
Pediatric patients
Safety and efficacy not established.
Patients with renal or hepatic impairment
Reduce dosage by 25%. Do not administer if bilirubin level exceeds 5 mg/dL.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
